OVAAL - ovarian adenocarcinoma amplified long non-coding RNA Gene

Also Known as OVAL; RMEL2; LINC01131

Species: Homo sapiens

Gene Type: ncRNA
Gene ID: 148756

About OVAAL

This gene has 6 transcripts (splice variants). Restricted expression toward heart (RPKM 1.1).

Related Diseases

Diseases Alias
Ovarian Cancer

  • Ovarian Carcinoma

  • Ovarian Neoplasm

  • Malignant Tumour Of Ovary

  • Cancer Of The Ovary

  • Epithelial Ovarian Cancer

  • Neoplasm Of Ovary

  • Ovarian Neoplasms

  • Ovarian Cancers

  • Malignant Neoplasm Of Ovary

  • Primary Malignant Neoplasm Of Ovary

  • Ovarian Cancer, Somatic

  • Malignant Ovarian Tumor

  • Ovary Neoplasm

  • Primary Ovarian Cancer

  • Tumor Of The Ovary

  • Malignant Neoplasm Of The Ovary

  • Malignant Tumor Of The Ovary

  • Ovarian Malignant Tumor

  • OC

  • Ovarian Carcinomas

  • Cancer, Ovarian

  • Cancer Of Ovary

  • Ovary Cancer

  • Ca Ovary
Leukorrhea

  • Discharge - Leukorrhea

  • Leukorrhea Of Vagina
Ovary Adenocarcinoma

  • Ovarian Adenocarcinoma

  • Adenocarcinoma Of The Ovary

  • Ovarian Adenoacanthoma

  • Adenocarcinoma Of Ovary
Melanoma

  • Malignant Melanoma

  • Cutaneous Melanoma

  • Naevocarcinoma

  • Malignant Melanomas
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (4)
Cat. No. Product Name Effect
Purity Phase
HY-150724C ODN 1018 sodium Agonist 97.49% Phase 2
HY-150724 ODN 1018 Agonist 99.28% Phase 2
HY-126467 TA-270 Inhibitor / Phase 2
HY-126294 Londamocitinib Inhibitor 99.79% Phase 1
Bioactive MoleculesInhibitory Antibodies (1)
Cat. No. Product Name Effect
Purity Phase
HY-P991961 REGN4659 Inhibitor / Phase 1

Pre-clinical Phase

Bioactive Molecules (98)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-W250978 Ovalbumins 99.17% Unkown
HY-P1489 OVA Peptide(257-264) 99.65% Unkown
HY-P1489A OVA Peptide(257-264) TFA 99.91% Unkown
HY-N0028 Forsythiaside A 99.79% Unkown
HY-119019 ASB14780 Inhibitor 99.58% Unkown
HY-N0668 Rubusoside Inhibitor 98.05% Unkown
HY-W250978A Ovalbumin, low endotoxin / Unkown
HY-P0286F1A FITC-OVA (323-339) TFA 98.22% Unkown
HY-P5411 OVA-T4 Peptide 99.59% Unkown
HY-NP055 Ovalbumin-Cy5 / Unkown
HY-NP030 Ovalbumin-PE / Unkown
HY-P3715 OVA peptide 99.93% Unkown
HY-P1771A OVA G4 peptide TFA 98.10% Unkown
HY-NP053 Ovalbumin-APC / Unkown
HY-P5410 OVA-Q4 Peptide 99.77% Unkown
HY-P2495A OVA (241-270) TFA 99.36% Unkown
HY-P11058 OVA(250-264) 98.14% Unkown
HY-W008234 N-Phthaloyl-β-alanine 99.18% Unkown
HY-N3522 Platycoside E Inhibitor 99.40% Unkown
HY-P2319A OVA-E1 peptide TFA Activator 98.05% Unkown
HY-131146 AMOZ 99.89% Unkown
HY-P5502A Influenza NP (311-325) TFA 96.94% Unkown
HY-161564 T4/OVA 95.0% Unkown
HY-NP056 Ovalbumin-AF488 / Unkown
HY-15131 PNRI-299 Inhibitor / Unkown
HY-158278A Aflatoxin B1/OVA 95% Unkown
HY-158286 Streptomycin/OVA / Unkown
HY-158292 Digoxin-OVA Inhibitor / Unkown
HY-159886 MG-C-30 Agonist 95.55% Unkown
HY-P0286F1 FITC-OVA (323-339) / Unkown
HY-P2495 OVA (241-270) / Unkown
HY-129639 L11204 Inhibitor / Unkown
HY-155819 M3/PDE4 modulator-1 / Unkown
HY-157198 Dinotefuran-NHCO-propionic acid / Unkown
HY-158267 Enrofloxacin/OVA Inhibitor / Unkown
HY-158268A 4-Hydroxynonenal/OVA / Unkown
HY-158272 Penicillin/OVA Inhibitor / Unkown
HY-158279 Gentamicin/OVA Inhibitor / Unkown
HY-158293 Toosendanin/OVA / Unkown
HY-158296 Tetracycline/OVA / Unkown
HY-158297 Histamine/OVA Activator / Unkown
HY-161001 AMOZ-CHPh-3-acid / Unkown
HY-161002 AMOZ-CHPh-4-O-C-acid / Unkown
HY-161003 AMOZ-CHPh-3-O-C-acid / Unkown
HY-161479 Melamine/OVA / Unkown
HY-161484 Penicillin G/OVA / Unkown
HY-161486 AOZ/OVA / Unkown
HY-161491 1-(2-Aminoethyl)-1H-pyrazol-4-ylphosphonic acid-linker/OVA / Unkown
HY-161492 Estradiol/OVA / Unkown
HY-161528 T3/OVA / Unkown
HY-161532 Eugenol/OVA / Unkown
HY-161534A Sulfadiazine-OVA / Unkown
HY-161540 Oxytetracycline/OVA / Unkown
HY-161554A Clenbuterol-OVA / Unkown
HY-161557A Ractopamine-OVA / Unkown
HY-161559 Sudan I/OVA / Unkown
HY-161561 PROMETON/OVA / Unkown
HY-161581 Metronidazole/OVA / Unkown
HY-161587 Chloramphenicol/OVA / Unkown
HY-162754 LMP7/LMP2-IN-1 Inhibitor / Unkown
HY-163026 Cyromazine-3-mercaptopropanoic acid / Unkown
HY-169478 Lipid N2-3L / Unkown
HY-172409 CB1R antagonist 2 / Unkown
HY-178716 PTPN2/1-IN-4 / Unkown
HY-179380 PTPN2-IN-2 / Unkown
HY-183209B Puromycin-OVA / Unkown
HY-183211 Glycyrrhizic acid/BSA / Unkown
HY-183211A Glycyrrhizic acid/OVA / Unkown
HY-B0015A Paclitaxel-OVA / Unkown
HY-N0045B Ginsenoside Rg1/OVA / Unkown
HY-N16024 FP-20 sodium Agonist / Unkown
HY-NP0209 Hydrocortisone-OVA / Unkown
HY-NP0211 DHT-OVA / Unkown
HY-NP0246 Sulfamerazine-OVA / Unkown
HY-NP0247A Sulfadimidine-OVA / Unkown
HY-NP0248A Ciprofloxacin-OVA / Unkown
HY-NP0249 Neomycin-OVA / Unkown
HY-NP0250A Kanamycin-OVA / Unkown
HY-NP0251A Ofloxacin-OVA / Unkown
HY-NP0252A Sulfamonomethoxine-OVA / Unkown
HY-NP0253 Salbutamol-OVA / Unkown
HY-NP0254 Thyroxin-OVA / Unkown
HY-NP0255A Amoxicillin-OVA / Unkown
HY-NP182 Folic acid/OVA / Unkown
HY-NP194A Cyclosporin A-OVA / Unkown
HY-NP209A Succinic acid-OVA / Unkown
HY-NP217 Valine/OVA / Unkown
HY-P10659 Self-assembling peptide pY1 / Unkown
HY-P11556 LR-13 / Unkown
HY-P1489B OVA Peptide(257-264) acetate salt / Unkown
HY-P1771 OVA G4 peptide / Unkown
HY-P2319 OVA-E1 peptide Activator / Unkown
HY-P5295 Cy3-Ova (323-339) / Unkown
HY-155499 AMOZ-CHPh-4-acid / Unkown
HY-163011 Dicamba-hex-5-ynoic acid / Unkown
HY-174484 OVA mRNA (5moU) / Unkown
HY-174485 OVA mRNA / Unkown
HY-D2428 OVA-PEG-Cy3 / Unkown
Bioactive MoleculesInhibitory Antibodies (1)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-P990258 Anti-Mouse CLEC9A/CD370 Antibody (7H11) Inhibitor 95% Unkown